GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Siemens Healthineers AG (OTCPK:SMMNY) » Definitions » Research & Development

Siemens Healthineers AG (Siemens Healthineers AG) Research & Development : $2,036 Mil (TTM As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Siemens Healthineers AG Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Siemens Healthineers AG's Research & Development for the three months ended in Dec. 2023 was $506 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was $2,036 Mil.

Siemens Healthineers AG Research & Development Historical Data

The historical data trend for Siemens Healthineers AG's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Siemens Healthineers AG Research & Development Chart

Siemens Healthineers AG Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Research & Development
Get a 7-Day Free Trial Premium Member Only 1,462.56 1,580.68 1,818.82 1,767.33 1,991.46

Siemens Healthineers AG Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 467.16 497.86 513.54 518.68 506.00

Siemens Healthineers AG Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,036 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Siemens Healthineers AG  (OTCPK:SMMNY) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Siemens Healthineers AG Research & Development Related Terms

Thank you for viewing the detailed overview of Siemens Healthineers AG's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Siemens Healthineers AG (Siemens Healthineers AG) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Siemens Healthineers AG (OTCPK:SMMNY) » Definitions » Research & Development
Comparable Companies
LSE:SN. LSE:NIOX LSE:MXCT LSE:EKF LSE:CREO LSE:BELL LSE:IUG LSE:IHC LSE:POLX LSE:SUN ABT SYK MDT BSX SZSE:300760 EW DXCM ZBH STE XAMS:PHIA
Traded in Other Exchanges
SEMHF:USA 1SHL:Italy SHLd:UK SHL:Germany SHL:Austria
Address
Siemensstr. 3, Forchheim, BY, DEU, 91301
Website
https://www.siemens-healthineers.com
Siemens Healthineers AG is engaged in the fields of diagnostic, therapeutic imaging, laboratory and point of care diagnostics as well as clinical consulting services. The imaging segment products equipment include magnetic resonance imaging, computed tomography, X-ray systems, molecular imaging and ultrasound. The portfolio of the Diagnostics segment includes; immunochemistry, hematology, coagulation, urinalysis, etc. Advanced Therapies segment products are designed to support image-guided minimally invasive treatments in cardiology, interventional radiology and surgery. Varian segment provides multi-modality cancer care technologies, solutions and services to oncology departments in hospitals and clinics. It caters and earns revenue from Europe, the Middle East, Africa, China and others.